From Zero Hedge:
ShareClinical trials are currently underway in the United States and Australia with Opie saying the procedure was minimally invasive—a factor he believes sets it apart from Musk’s Neuralink.
“We don’t need to remove the scalp and skull or put electrodes directly into delicate brain tissue,” he said in comments obtained by AAP.
“We’ve come up with a clever way of getting to the right place in the brain just by using the body’s naturally occurring highways and blood vessels.” He added this ensured patients recovered faster as well from the procedure. So far, four Australian paralysis patients have received implants since undergoing the procedure at Royal Melbourne Hospital in 2020.
“All of those patients were able to control a computer with their mind,” he said. “And there were no serious device-related effects.” The first U.S. patient was treated in July 2022 at Mount Sinai Hospital in New York after Synchron received approval from the U.S. Food and Drug Administration last year. In contrast, Musk’s Neuralink has yet to receive approval from the body and is also facing questions over potential animal welfare violations. Musk had wanted to start human trials in six months, yet the billionaire is also reported to have approached Synchron about a potential investment. (Read more.)
No comments:
Post a Comment